Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）

Inclusion criteria

• Male or female patients aged 18 to 75 (including 18 and 75) at the time of Informed Consent
• Pathologically confirmed advanced colorectal adenocarcinoma (all the other histological types are excluded)
• Treatment failure in previously received standard therapy (at least two lines), which must include 5-Fu, irinotecan and oxaliplatin

Definition of "treatment failure":

A.Disease progression during experimental drug treatment or within 3 months after the last treatment, with definite imaging or clinical evidences;

B.For patients abandoning chemotherapy because of intolerance of advent events, hematologic toxicity is required to reach ≥Grade IV (platelet decrease ≥ Grade III ), and nonhematologic toxicity is required to reach ≥Grade III , according to NCI CTCAE 4.0. Furthermore, the original treatment should be not tolerated any more when it is repeated to the same patient, judged by investigators.

Note:

A.When adjuvant therapy including oxaliplatin was previously used, at least 9 courses of FOLFOX (2 weeks regimens), 6 courses of CapeOX (3 week regimen), or 750mg/m^2 cumulative consumption of oxaliplatin, are required. Adjuvant therapy will be regarded as the first-line treatment when disease progressed during or within 6 months after treatments

B.Monoclonal antibody drugs (bevacizumab, cetuximab, panitumumab, aflibercept, etc.) are allowed to combine with prior chemotherapy.

• At least one measurable targeting lesion according to RECIST 1.1 (The diameter of tumor and lymph node lesion should be ≥ 10 mm and 15mm, respectively, with scanning layer ≤ 5 mm and without local treatment)
• Eastern Cooperative Oncology Group (ECOG) performance status:0-1.
• Life expectancy ≥ 3 months
• Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:

A.Routine blood test:

• Hemoglobin > 90g/L (not received blood transfusion or drugs to incraese RBC, Hb, WBC and PLT in 14 days before screening )
• Neutrophils > 1.5×10^9/L
• Platelets > 100×10^9/L

B. Blood biochemistry:

• Total bilirubin < 1.25×the upper limit of normal (ULN)
• Serum transaminase ≤ 2×ULN (≤ 5×ULN, If existing liver metastases)
• Creatinine clearance rate ≥ 60ml/min (Cockcroft-Gault Formula)

C.Doppler echocardiography assessment: Left ventricular ejection fraction (LVEF) ≥ 50%

• Having recovered from impairments of other therapy before taking research drugs (more than 6 weeks from the last treatment of Nitroso or MMC, more than 4 weeks from the last treatment of other cytotoxic drugs, targeted drugs, radiotherapy or operation, with completely healed wound, more than 2 weeks from the last treatment of Chinese traditional and patent medicine)
• Signed and dated informed consent
• Good compliance of patients and agreement of their family members to cooperate on the follow-up of survival.

Exclusion criteria

• Second malignancies, except for cured skin basal cell carcinoma and carcinoma in-situ of uterine cervix, before or during screening
• Previously received therapy of tyrosine kinase inhibitor agent targeting at VEGFR, e.g. famitinib, sorafenib, sunitinib, regorafenib
• Having joined in other clinical trials within 4 weeks
• Factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.)
• Having haemorrhage history, ≥ Grade Ⅲ (NCI CTCAE 4.0 ) haemorrhage occurred within 4 weeks before screening
• Known central nervous system (CNS) metastasis or having CNS metastasis history before screening. CT or MRI scan should be received 28 days before randomization when CNS metastases is clinically suspected
• Uncontrolled hypertension with single medical therapy (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg), History of unstable angina pectoris or newly diagnosed unstable angina pectoris within 3 months before screening, myocardial infarction events within 6 months before screening, Arrhythmias (QTcF: ≥450ms in male, ≥ 470ms in female) needed long-term treatment of drugs, ≥ class II cardiac insufficiency by New York Heart Association (NYHA) classification
• urinary protein ≥ ++ or 24-hour urinary protein ≥ 1.0 g
• Chronic untreated wounds or fractures
• Tumor invasion around major vessels shown by imaging, high risk of major vascular invasion leading to massive hemorrhage judged by investigators
• Abnormal international normalized ratio (INR) of patients with coagulation dysfunction and hemorrhagic tendency at 14 days before randomization. Application of anticoagulants or vitamin K antagonists such as warfarin, heparin or its analogues. However, low doses of warfarin (1mg orally, once daily) or aspirin (between 80mg to 100mg daily) can be used for prevention on the premise of INR ≤ 1.5
• Artery/venous thromboembolic events occurred within 1 year before screening, such as cerebral vascular accident (including transient ischemic attack), deep vein thrombosis (except for recovered venous thrombosis judged by investigators, which was caused by venous catheter in previous chemotherapy) and pulmonary embolism, etc.
• All female patients who are not surgically sterilized or postmenopausal refusing to take a reliable method of birth control during the study and within 6 months after the last dose of test article. All female patients in breastfeeding period or in child-bearing period with a positive urine or serum pregnancy test result before randomization. All male subjects who are not surgically sterilized refusing to take a reliable method of birth control during the study and within 6 months after the last dose of test article.
• Preexisted thyroid dysfunction, thyroid function cannot be controlled within normal range even using medical therapy
• History of psychiatric drug abuse and addiction, dysphrenia
• Symptomatic pleural effusion, hydropericardium or ascites needed clinical intervention or being stable less than 4 weeks.
• History of Immunodeficiency, acquired or congenital immunodeficiency, history of organ transplantation
• Known active HBV or HCV infection companion with hepatic dysfunction
• Concomitant disease judged by investigators that may bring serious harm to the safety of patients or the completion of this study